INTRODUCTION {#s1}
============

Lung cancer, especially non-small cell lung cancer (NSCLC), is currently the leading cause of cancer-related death worldwide \[[@R1]\]. Recent advancements in targeted therapy have led to a major paradigm shift in the treatment of advanced NSCLC \[[@R2]\]. Molecularly targeted drugs such as erlotinib and gefitinib have thus greatly improved the clinical outcome of advanced NSCLC patients harboring sensitive epidermal growth factor receptor (EGFR) gene mutations \[[@R3]\]. Two major types of EGFR kinase mutations include exon-19 deletions and L858R mutation in exon 21 \[[@R4], [@R5]\].

Programmed death 1 (PD-1) is a co-inhibitory receptor expressed on the membrane of activated T and B cells \[[@R6]\], which plays a crucial role in tumor immune escape \[[@R7], [@R8]\]. Programmed cell death-ligand 1 (PD-L1) is the major ligand for PD-1 and is expressed in a variety of cancers \[[@R7], [@R9]\]. PD-L1 has been shown to be involved in the negative regulation of immune response through PD-1 receptor and has been thought to be an important strategy for cancer cells to evade host immune surveillance. Cancer cells expressing PD-L1 have been shown to increase apoptosis of antigen-specific human T-cell clones and to inhibit CD4 and CD8 T-cell activation *in vitro* \[[@R10]-[@R12]\].

Currently, some studies demonstrated that PD-L1 was expressed in 19.63%-65.38% of NSCLC \[[@R2], [@R13]-[@R16]\]. Several studies suggested that PD-L1 expression portended inconsistent survival outcomes \[[@R17]\]. For example, a study showed that tumor with a high level of PD-L1 expression was associated with significantly shorter overall survival (OS) in NSCLC patients \[[@R2]\], while another report showed positive PD-L1 was significantly associated with better survival outcome \[[@R15]\]. Now, the molecular regulatory mechanism of PD-L1 isn\'t comprehensive enough, though two studies found that mutant EGFR could induce PD-L1 expression *in vitro* and *vivo*, and EGFR tyrosine kinase inhibitors (EGFR-TKIs) could down-regulate PD-L1 expression \[[@R2], [@R16]\]. It is therefore of significance to study the association between EGFR driver mutation and PD-L1. Even more, the incidence of EGFR mutations is higher in East Asian patients than in Caucasian patients (30% versus 8%) \[[@R4]\], and there are no studies examining the relationship between PD-L1 expression and efficacy in patients treated with EGFR-TKIs in China. Therefore, we tried to investigate the impact of PD-L1 expression on EGFR-TKIs\' efficacy and prognosis in Chinese advanced NSCLC patients, emphasizing on the EGFR mutational status.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

A total of 170 eligible patients with advanced NSCLC were included in the present study (Figure [1](#F1){ref-type="fig"}). The mean age at diagnosis was 57.09 years (range, 32--80 years) (Table [1](#T1){ref-type="table"}). Seventy-seven (45.3%) of the patients were female and ninety-three (54.7%) were male. Fifty-seven (33.5%) patients were smokers. Nine (5.3%) patients and 161 (94.7%) patients were diagnosed at stage IIIB and stage IV, respectively. In the current research, 99 patients harbored EGFR mutation and the remaining 71 patients were EGFR wild type. With regard to EGFR mutation status, 40 patients harbored a deletion in exon 19 and 47 patients had an L858R missense mutation in exon 21. 12 were uncommon mutation.

![Flowing chart of the enrollment\
Abbreviations: EGFR, epidermal growth factor receptor; EGFR-TKIs, EGFR-tyrosine kinase inhibitors; PD-L1, programmed cell death-ligand 1.](oncotarget-06-14209-g001){#F1}

###### Clinicopathological characteristics of patients with NSCLC (n = 170) and their relationship with PD-L1 expression

  Parameter            PD-L1 positive   PD-L1 negative                                 
  -------------------- ---------------- ---------------- ---- ---- ---- ---- ---- ---- -----------
  **Age**                                                                              
   ≤50y                28               6                17   5    17   3    9    5    0.546
   \>50y               84               19               51   14   41   12   22   7    
  **Gender**                                                                           
   female              56               13               38   5    21   8    11   2    0.087
   male                56               12               30   14   37   7    20   10   
  **Smoking**                                                                          
   no                  77               21               50   6    36   14   15   7    0.382
   yes                 35               4                18   13   22   1    16   5    
  **Pathology**                                                                        
   ADC                 96               24               58   14   49   14   25   10   0.830
   non-ADC             16               1                10   5    9    1    6    2    
  **Stage**                                                                            
   III B               7                1                5    1    2    0    2    0    0.680
   IV                  105              24               63   18   56   15   29   12   
  **EGFR status**                                                                      
   wild type           42               5                21   16   29   3    16   10   0.330
   exon 19 del         26               6                19   1    14   7    6    1    
   exon 21 L858R       35               11               23   1    12   4    7    1    
   unknown classical   9                3                5    1    3    1    2    0    
  **EGFR-TKI**                                                                         
   1st line            61               16               37   8    22   8    12   2    **0.041**
   ≥2nd line           51               9                31   11   36   7    19   10   
  **Pathology=ADC**                                                                    
  EGFR wild type       32               4                15   13   24   3    13   8    0.067
  EGFR mutation        64               20               43   1    25   11   12   2    

Notes: H-score ≥ 5 was used as cut-off value to distinguish positive and negative expression of PD-L1.

Abbreviations: PD-L1, programmed cell death-ligand 1; ADC, adenocarcinoma; non-ADC, non-adenocarcinoma; EGFR, epidermal growth factor receptor; EGFR-TKIs, EGFR-tyrosine kinase inhibitors.

Correlations between PD-L1 expression and baseline characteristics {#s2_2}
------------------------------------------------------------------

Immunohistochemical staining for PD-L1 was found at the membrane or in the cytoplasm (or both) of tumor cells (Figure [2A](#F2){ref-type="fig"}). As shown in Table [1](#T1){ref-type="table"}, PD-L1 is over expressed in 65.9% (112/170) of advanced NSCLC patients. The relationship between PD-L1 expression and age, gender, histopathological type, tumor stage and EGFR mutational status was not significant, except for the line of EGFR TKIs (*P* = 0.041). However, in subgroup of lung adenocarcinoma, there was a borderline difference between PD-L1 expression level and EGFR mutational status (32/56 (57.1%) for wild type and 64/89 (71.9%) for mutant type, respectively, p=0.067).

![(**A**) Positive programmed cell death-ligand 1 (PD-L1) immunohistochemical staining with a membranous pattern. (**B**) Negative PD-L1 immunohistochemical staining. Original magnification, 20 ×.](oncotarget-06-14209-g002){#F2}

Relationships between PD-L1 expression and the EGFR-TKIs\' efficacy {#s2_3}
-------------------------------------------------------------------

The association between the efficacy of EGFR-TKIs with PD-L1 expression as well as other clinicpathologic factors in advanced NSCLC patients was summarized in Table [2](#T2){ref-type="table"}. There was no significant relationship between objective response rate (ORR) and PD-L1 expression, as well as age, gender, histopathological type, stage and TKI line. However, patients with mutant EGFR had better ORR than those with wild-type EGFR (odds ratio (OR), 0.266; 95% confidence interval (95%CI), 0.114 to 0.621; p =0.002) and non-smokers also had higher ORR than smokers did (OR, 4.667; 95% CI, 1.716 to 12.693; p = 0.003). These results were in accordance with the results of multivariate analysis. Besides, we examined the association between a variety of factors and disease control rate (DCR). We found that there was no significant difference between DCR and PD-L1 status (OR, 0.783; 95% CI, 0.350 to 1.751; p =0.551). Whereas, DCR was significantly higher in women than that in men (OR, 3.478; 95% CI, 1.407 to 8.600; P=0.007), in never-smokers than that in smokers (OR, 3.55; 95% CI, 1.589 to 7.930; P=0.002), and in those with EGFR mutation than that in those EGFR with wild type (OR, 0.092; 95% CI, 0.033 to 0.256; P\<0.001) (Table [2](#T2){ref-type="table"}). And the multivariate analysis revealed that EGFR mutation positivity was an independent factor (OR, 0.113; 95% CI, 0.038 to 0.342; P=0.007). We further divided patients into two subgroups: (I) EGFR wild type (n=71) and (II) EGFR mutant (n=99). No significant differences in two subgroups were found between PD-L1 expression and ORR (OR, 0.854; 95% CI, 0.187 to 3.891; P=0.838 and OR, 1.765; 95% CI, 0.715 to 4.353; P=0.218 for group I and group II, respectively), as well as PD-L1 expression and DCR (OR, 1.169; 95% CI, 0.436 to 3.137; P=0.756 and OR, 0.604; 95% CI, 0.096 to 3.822; P=0.593 for group I and group II, respectively).

###### The association between PD-L1 expression and EGFR-TKIS\' efficacy in univariate and multivariate logistic regression analysis[\#](#tfn-001){ref-type="table-fn"}

  Parameter                     ORR   DCR                                                                                                                                                         
  ----------------------------- ----- ----- ----- ------- -------------- ----------- ------- -------------- ----------- --- ---- ----- ------- -------------- ------------- ------- ------------- -------------
  **Age**                                                                                                                                                                                         
   ≤50                                9     36    0.758   0.329-1.748    0.516       0.663   0.264-1.666    0.382           10   35    0.707   0.304-1.645    0.421         0.495   0.181-1.358   0.172
   \>50                         1     31    94                                                                          1   21   104                                                              
  **Gender**                                                                                                                                                                                      
   female                             21    56    1.461   0.717-2.974    0.296       0.541   0.220-1.331    0.181           7    70    3.478   1.407-8.600    **0.007**     1.899   0.528-6.837   0.326
   male                         1     19    74                                                                          1   24   69                                                               
  **Smoking**                                                                                                                                                                                     
   no                                 35    78    4.667   1.716-12.693   **0.003**   5.776   1.763-18.863   **0.004**       13   100   3.55    1.589-7.930    **0.002**     1.942   0.612-6.154   0.260
   yes                          1     5     52                                                                          1   18   39                                                               
  **Pathology**                                                                                                                                                                                   
   ADC                                38    107   4.084   0.919-18.150   0.064       3.834   0.793-18.538   0.095           24   121   1.961   0.738-5.207    0.177         1.348   0.439-4.142   0.602
   non-ADC                      1     2     23                                                                          1   7    18                                                               
  **Stage**                                                                                                                                                                                       
   IIIB                               1     8     0.391   0.047-3.225    0.383       0.206   0.023-1.877    0.161           1    8     1.832   0.221-15.208   0.575         0.576   0.046-7.175   0.668
   IV                           1     39    122                                                                         1   30   131                                                              
  **EGFR**                                                                                                                                                                                        
   wild type                          8     63    0.266   0.114-0.621    **0.002**   0.351   0.137-0.904    **0.030**       26   42    0.092   0.033-0.256    **\<0.001**   0.113   0.038-0.342   **\<0.001**
   mutation                     1     32    67                                                                          1   5    97                                                               
  **EGFR-TKI**                                                                                                                                                                                    
   1st line                           24    59    1.805   0.878-3.711    0.108       1.863   0.798-4.349    0.150           10   73    2.323   1.020-5.291    **0.045**     1.394   0.525-3.702   0.506
   ≥2nd line                    1     16    71                                                                          1   21   66                                                               
  **PD-L1**                                                                                                                                                                                       
   negative                           15    43    1.214   0.581-2.537    0.606       1.674   0.711-3.939    0.238           12   46    0.783   0.350-1.751    0.551         1.109   0.445-2.764   0.824
   positive                     1     25    87                                                                          1   19   93                                                               
  **EGFR wild-type subgroup**                                                                                                                                                                     
   PD-L1 negative                     3     26    0.854   0.187-3.891    0.838                                              10   19    1.169   0.436-3.137    0.756                               
   PD-L1 positive               1     5     37                                                                          1   16   26                                                               
  **EGFR mutant subgroup**                                                                                                                                                                        
   PD-L1 negative                     12    17    1.765   0.715-4.353    0.218                                              2    27    0.604   0.096-3.822    0.593                               
   PD-L1 positive               1     20    50                                                                          1   3    67                                                               

A total of 170 non-small cell lung cancer patients were included.

Abbreviations: ORR, objective response rate; DCR, disease control rate; PR, partial response; SD, stable disease; PD, progressive disease ; OR, odd ratio; 95%CI, 95% confidence intervals; ADC, adenocarcinoma; non-ADC, non-adenocarcinoma; EGFR, epidermal growth factor receptor; EGFR-TKI, EGFR-tyrosine kinase inhibitor; PD-L1, programmed cell death-ligand 1.

Survival analyses is in NSCLC patients {#s2_4}
--------------------------------------

The median overall survival of the whole patients was 39.9 months. Kaplan--Meier analysis revealed that overall patients with positive PD-L1 and negative PD-L1 expression had no significant difference in OS and progression-free survival (PFS) (Figure [3A and 3D](#F3){ref-type="fig"}). To investigate the PD-L1\'s clinical significance, we further divided the patients into two groups: EGFR mutation and EGFR wild type. In EGFR mutation group, PFS and OS of patients with positive PD-L1 tended to be longer than patients with negative PD-L1, although statistical significance was not achieved (Figure [3B and 3E](#F3){ref-type="fig"}). In EGFR wild type group, negative PD-L1 patients have longer OS than positive-PD-L1 patients (P=0.029) (Figure [3C](#F3){ref-type="fig"}), while no significant difference in PFS was observed (Figure [3F](#F3){ref-type="fig"}). Exploratory analysis was done to validate the prognostic role of PD-L1 in subgroups defined by age, sex, smoking, pathology, stage of disease, EGFR mutation, and EGFR-TKI\'s lines (Figure [4](#F4){ref-type="fig"}). We found that patients with positive PD-L1 expression had signal better prognosis in EGFR mutation subgroup, contrary to EGFR wild-type group. To determine the prognostic value of PD-L1 expression, we carried out univariate and multivariate analyses using the Cox regression model. For PFS and OS, EGFR mutation remained the independent factor for better prognosis (hazard ratio (HR), 0.419; 95% CI, 0.262-0.672; P \<0.001 for PFS and HR, 0.499; 95% CI, 0.264-0.942; P=0.032 for OS, respectively) (Table [3](#T3){ref-type="table"}). In subgroup multivariate analysis, we found that the high level PD-L1 can be considered as a poor prognostic indicator of OS for EGFR wild-type patients (HR, 3.738; 95% CI, 1.341-10.419; P=0.012) ([Supplementary table 1](#SD1){ref-type="supplementary-material"}).

![Kaplan-Meier curves of overall survival (OS) and progression-free survival (PFS) according to programmed cell death-ligand 1 (PD-L1) expression status in non-small cell lung cancer (NSCLC) patients\
The P value for the difference between the two curves was determined by the log-rank test. Notes: (**A**) OS for overall population. (**B**) OS for patients with EGFR mutation. (**C**) OS for patients with EGFR wild type. (**D**) PFS for overall population. (**E**) PFS for patients with EGFR mutation. (**F**) PFS for patients with EGFR wild type.](oncotarget-06-14209-g003){#F3}

![Forest plot of overall survival (OS) and progression-free survival (PFS) according to programmed cell death-ligand 1 (PD-L1) expression status in subgroup analysis\
Abbreviations: HR, hazard ratio, HR \<1 implies a lower risk of progression or death for patients; 95% CI, 95% confidence intervals.](oncotarget-06-14209-g004){#F4}

###### Univariate and multivariate analyses of OS and PFS in NSCLC patients

  Parameter       OS   PFS                                                                                                                                           
  --------------- ---- ----- ------- ------------- ----------- ------- ------------- ----------- --- ----- ------- ------------- ------------- ------- ------------- -------------
  **Age**                                                                                                                                                            
   ≤50y           1    45                                                                        1   45                                                              
   \>50y               125   2.552   1.082-6.019   **0.032**   2.602   1.078-6.279   **0.033**       125   0.77    0.483-1.229   0.274         0.69    0.428-1.112   0.128
  **Gender**                                                                                                                                                         
   female         1    77                                                                        1   77                                                              
   male                93    1.737   0.963-3.131   0.066       1.346   0.649-2.795   0.425           93    1.779   1.147-2.760   **0.010**     1.245   0.704-2.200   0.451
  **Smoking**                                                                                                                                                        
   no             1    113                                                                       1   113                                                             
   yes                 57    1.718   0.921-3.207   0.089       1.218   0.552-2.684   0.626           57    1.832   1.179-2.846   **0.007**     1.364   0.761-2.445   0.297
  **Pathology**                                                                                                                                                      
   ADC            1    145                                                                       1   145                                                             
   non-ADC             25    1.349   0.604-3.017   0.465       1.548   0.680-3.520   0.298           25    1.59    0.894-2.826   0.114         1.396   0.776-2.508   0.265
  **Stage**                                                                                                                                                          
   IIIB           1    9                                                                         1   9                                                               
   IV                  161   1.199   0.370-3.890   0.762       1.030   0.291-3.650   0.963           161   1.627   0.594-4.455   0.344         0.822   0.284-2.382   0.719
  **EGFR**                                                                                                                                                           
   wild type      1    71                                                                        1   71                                                              
   mutation            99    0.485   0.271-0.868   **0.015**   0.499   0.264-0.942   **0.032**       99    0.365   0.237-0.562   **\<0.001**   0.419   0.262-0.672   **\<0.001**
  **EGFR-TKI**                                                                                                                                                       
   1st line       1    83                                                                        1   83                                                              
   ≥2nd line           87    1.338   0.751-2.384   0.323       1.562   0.839-2.906   0.159           87    1.941   1.257-2.996   **0.003**     1.756   1.099-2.806   **0.019**
  **PD-L1**                                                                                                                                                          
   negative       1    58                                                                        1   58                                                              
   positive            112   1.472   0.776-2.792   0.236       1.901   0.953-3.790   0.068           112   1.003   0.641-1.569   0.990         1.315   0.831-2.080   0.242

Abbreviations: OS, overall survival; PFS, progression-free survival; HR, hazard ratio; 95%CI, 95% confidence intervals; ADC, adenocarcinoma; non-ADC, non-adenocarcinoma; EGFR, epidermal growth factor receptor; EGFR-TKI, EGFR-tyrosine kinase inhibitor; PD-L1, programmed cell death-ligand 1.

DISCUSSION {#s3}
==========

NSCLC is partially characterized by driver mutation-defined molecular subsets, each with distinct clinicopathologic features and potentials for targeted therapies. In the present study, we found that PD-L1 was over-expressed in 65.9% of advanced NSCLC samples and positive PD-L1 tended to be associated with EGFR mutation. We also revealed that there was no significant correlation between expression of PD-L1 and curative effect of EGFR TKIs (ORR and DCR). In EGFR mutation group, PFS and OS of patients positive for PD-L1 tended to be signal better than that of patients who were negative, although statistical significance was not achieved. For patients with wild type EGFR, PD-L1-negative NSCLC patients had longer overall survival than PD-L1-positive ones.

In previous studies, researchers have demonstrated that activation of the EGFR pathway induced PD-L1 expression \[[@R2], [@R16], [@R18]\], and found PD-L1 was significantly higher in patients with the following characteristics: women, never smokers and with adenocarcinoma \[[@R2], [@R16]\]. All these characteristics are hallmarks of EGFR mutations. In present study, we also found a borderline association between high PD-L1 expression and EGFR mutation in lung adenocarcinoma, while no significant relationship between ages, gender, smoking history and PD-L1 expression was found in NSCLC patients. The difference between the present and previous studies may be due to several reasons. First, the sample size varied among different studies and all data were retrospectively collected, resulting in potential bias. Second, the heterogeneity of baseline characteristics among these studies had also affected their outcomes, such as pathological stage and geographical distribution. Third, the threshold of positive PD-L1 expression was also different from each other in these studies. Fourth, the specificity and reproducibility of the commercially available antibodies and variations in Immunohistochemical technique weren\'t thoroughly assessed \[[@R15]\]. Thus, for future studies, more efforts to standardize a quantitative assay for PD-L1 expression are warranted.

In EGFR wild-type lung cancer, immune evasion induced by PD-L1 played an important role. PD-1/PD-L1 pathway has been recognized as a key mechanism of immune evasion. Cancer cells can evade host immune systems by expressing certain ligands to down-regulate cytotoxic T lymphocytes through inhibitory pathways, which are usually initiated by ligand-receptor interactions \[[@R19]\]. PD-1 is one immune checkpoint expressed on the surface of T-cells upon activation \[[@R20]\]. PD-L1 is the major ligand for PD-1 and is expressed in various type of cancers \[[@R9]\]. PD-1/PD-L1 interaction is regarded as an inhibitory checkpoint for T-cell activation at its initial stage. In the present report, our data revealed that high PD-L1 expression was correlated with poor prognosis in EGFR wild-type patients but not in EGFR mutant population. This finding indicated that EGFR wild-type NSCLC failed to be controlled by the immune system which is inhibited by PD-L1 mediated antitumor activity. Then cancer cells can evade host immune responses by expressing PD-L1 to down-regulate T-cell activation in tumorous microenvironment \[[@R9]\], allowing cancer cells to survive and progress. Therefore, PD-L1 status was a significant prognostic factor for patients with EGFR wild type. This implicated that for this subset of population (EGFR wild-type and PD-L1 over-expression), PD-L1 blocker may be an alternative therapeutic strategy. For future clinical applications, more evidences to verify the feasibility are warranted.

According to previous studies, we could explain why patients with positive for PD-L1 expression tended to have better OS than PD-L1 negative ones in EGFR mutant NSCLC patients. The most possible reason was the cross interaction between EGFR pathway and PD-L1. A study by Azuma K et al. \[[@R2]\] found that inhibition of EGFR signaling with erlotinib led to down-regulation of the expression of PD-L1 in EGFR mutant NSCLC cells but not in those with wild-type EGFR, indicating that the expression of PD-L1 might be dependent on EGFR signaling conferred by activating EGFR mutations. In another research, Akbay EA et al. \[[@R16]\] also found that PD-L1 expression was reduced by EGFR inhibitors in NSCLC cell lines with activated EGFR. Therefore, for EGFR mutant NSCLC patients, EGFR-TKIs could perform a dual therapeutic response. The down-regulation of PD-L1 expression and the consequent restoration of an antitumor immune response might contribute to the durable therapeutic response. EGFR activation up regulated PD-L1 through MAPK signaling pathway. As previously reported, EGFR remarkably increased the activity of ERK1/2 and AKT which are involved in the proliferation, anti-apoptosis, and invasion of tumor cells \[[@R21], [@R22]\]. Chen N et al. \[[@R23]\] further demonstrated that the up-regulation of PD-L1 mediated by EGFR activation was associated with the activation of ERK1/2/c-Jun. By inhibiting p-ERK1/2, PD-L1 decreased following p-ERK1/2/p-Jun down-regulation in a clear dose-dependent manner \[[@R23]\]. This detailed mechanism confirmed that EGFR mutant NSCLC patients may benefit not only from direct tumor killing effect of EGFR-TKIs but also indirectly from immune enhancement after EGFR-TKIs treatment.

As we known, targeted therapy usually have rapid and impressive response rates but modest progression-free survival while immunotherapy can achieve durable tumor control but associated with lower response rates \[[@R24]\]. To address this, investigators have proposed combining these strategies. There is a scientific rationale supporting the combination of targeted therapy and immunotherapy \[[@R25]\]. For patients with melanoma, the concept of potential synergy with BRAF-targeted therapy and immunotherapy is being empirically investigated in clinical trials \[[@R26]-[@R28]\]; however, much remains to be learned. Response data from these initial trials are not mature, and additional trials will be needed to determine the appropriate sequence, schedule, and duration of therapy if there is evidence of synergy. Yet, there were no data about the combinatorial strategies of EGFR-TKIs with anti-PD-1/PD-L1. While there were no direct verified evidences, this combining therapy may be an alternative strategy in EGFR mutant NSCLC. In the future, more well-designed *in vitro* and *vivo* studies to explore molecular mechanisms of combining EGFR-TKIs and anti-PD-1/PD-L1 antibodies are urgently required. Randomized clinical trials to instruct how best to combine therapeutic agents are also needed.

Currently, though gefitinib and erlotinib are regarded as the first line treatment of classical EGFR mutant NSCLC patients, a majority of them eventually develop secondary resistance to gefitinib and erlotinib. Previous treatment options for EGFR-TKIs resistance include CO-1686 \[[@R29]\], AZD9291 \[[@R30]\] and HM61713 \[[@R31]\] for EGFR T790M and EGFR-TKIs plus c-met inhibitors for c-met amplification \[[@R32]\]. However, the role of immunotherapy in EGFR-TKIs-resistant patients has not been revealed. Chen N et al. \[[@R23]\] demonstrated that the protein level of PD-L1 in EGFR-mutant NSCLC cell lines (PC-9, HCC827 and H1975) was significantly higher than that in EGFR-wild type cell lines (A539, H1993). Moreover, the expression of PD-L1 was the highest in resistant cells (H1975 cells, with EGFR-T790M mutation). Anti- PD-1/PD-L1 axis could significantly decrease the viability of gefitinib resistant H1975 cells. This implied that blockade of PD-1/PD-L1 might be a promising optional treatment for NSCLC patients with EGFR mutation, especially for EGFR-TKIs resistant NSCLC patients. Future clinical studies are needed to test the feasibility.

Notably, this is the first study to assess the relationship between PD-L1 expression and prognosis as well as efficacy in Chinese advanced NSCLC patients with treatment of EGFR-TKIs. We prove that high PD-L1 expression is likely to be associated with the presence of EGFR mutation in advanced lung adenocarcinoma. Moreover, PD-L1 over-expression can be considered as a poor prognostic indicator of OS in EGFR wild-type patients treated with EGFR-TKIs.

PATIENTS AND METHODS {#s4}
====================

Patients {#s4_1}
--------

A total of 3543 consecutive NSCLC patients who have taken oral EGFR-TKIs at Sun Yat-sen University Cancer Center (Guangzhou, China) from January 2008 to March 2014 were screened in the study. Patients were recruited if they met the following conditions: 1, treated with EGFR-TKIs; 2, stage 3b/4 NSCLC or recurrent disease after surgery or chemotherapy; 3, with known EGFR mutational status; 4, having detailed medical records and had enough tumor tissue samples for immunohistochemical staining of PD-L1. Finally, a total of 170 patients were eligible. Figure [1](#F1){ref-type="fig"} summarized the process of patients\' selection. Baseline clinical and pathological features were collected, as well as tissue specimens from surgery or biopsy. The clinicopathological features of the patients included age, gender, smoking status, pathological type, Union for International Cancer Control (UICC) stage (the seventh edition), EGFR mutation status and EGFR-TKI treatment history. Fifty years old was chosen as the cutoff for dividing the high or low age group (50y was low and 50y was high, respectively). Smoking history was noted as yes or no (no-smoking refers to patients who had never smoked in their lifetime). Pathological subtype was divided into adenocarcinoma or non-adenocarcinoma. All patients were restaged according to the seventh edition of UICC Staging System for NSCLC. EGFR exon 19 deletions or exon 21 base substitutions were considered as classical EGFR mutations by fluorescent quantitative polymerase chain reaction (PCR). The study was approved by the Institutional Review Board of Sun Yat-Sen University Cancer Center (Guangzhou, China). All the patients had provided written informed consent before samples were collected.

Immunohistochemistry analyses {#s4_2}
-----------------------------

Immunohistochemical staining was performed using rabbit monoclonal anti-human antibody (E1L3N™, Cell Signaling Technology, Danvers, MA, 1:200) for testing the expression of PD-L1 in human NSCLC specimens. Five-μm-thick Sections were cut from the formalin-fixed, paraffin-embedded (FFPE) tumor block and then routinely deparaffined and rehydrated. For antigen retrieval, slides were heated in a microwave oven for 30 minutes in citrate buffer solution (pH=7.4) and cooled slowly at room temperature for 20 minutes. After blocking the activity of endogenous peroxidase with 3% hydrogen peroxide for 8 minutes, the sections were treated with primary antibodies and incubated for overnight (more than 12 hours). Subsequently, the slides were rinsed in PBS three times and incubated in HRR-linked secondary antibodies. After incubation, slides were washed again with PBS and then visualized using diaminobenzidine. Finally, Mayer\'s hematoxylin was used to counterstain the sections, which were then dehydrated and mounted.

Two pathologists who were blinded to the clinical or pathological information of these patients independently assess the expression of PD-L1. Semiquantitative H score (maximum value of 300 corresponding to 100% of tumor cells positive for PD-L1 with an overall staining intensity score of 3) was defined as multiplying the percentage of stained cells by an intensity score (0, absent; 1, weak; 2, moderate; and 3, strong). A 5% proportion of membrane-positive tumor cells which were defined as H-score ≥ 5 have been used as cutoff for PD-L1 positivity \[[@R33], [@R34]\], as this cut-point is reported to be associated with clinical response to anti-PD-1 therapy \[[@R34]\].

Statistical analysis {#s4_3}
--------------------

All the statistical analysis was performed using SPSS 20.0 for Windows (IBM, Armonk, NY). The cut-off value of age were obtained by X-tile software (Version 3.6.1, Yale University, New Haven, CT), taking clinical expertise into consideration. Pearson\'s chi-squared test or continuity correction test was used to assess correlations between PD-L1 expression and clinicopathologic variables. Univariate and multivariate logistic regression analysis were used to test the association between PD-L1 expression and EGFR-TKIs\' efficacy (ORR and DCR). OS was defined as the time from diagnosis to the end of the follow-up (August 2014). And PFS was the time from beginning to taking TKI to recurrence or last follow-up. OS and PFS analyses were estimated with Kaplan-Meier method and multivariable analyses were performed to assess survival difference. The results of ORR and DCR were reported with OR and its 95% CI, while prognostic results were reported with HR and its 95% CI. OR \> 1 indicated that EGFR-TKI was more effective in PD-L1 positive patients. HR \< 1 implied a lower risk of progression or death for patients with positive expression of PD-L1. A two sided p-value of \<0.05 was considered statistically significant.
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